Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

PURPOSE: B-cell leukemia/lymphoma-2 (BCL-2) overexpression is common in many non-Hodgkin lymphoma (NHL) subtypes. A phase I trial in patients with NHL was conducted to determine safety, pharmacokinetics, and efficacy of venetoclax, a selective, potent, orally bioavailable BCL-2 inhibitor. PATIENTS A...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:J Clin Oncol
Huvudupphovsmän: Davids, Matthew S., Roberts, Andrew W., Seymour, John F., Pagel, John M., Kahl, Brad S., Wierda, William G., Puvvada, Soham, Kipps, Thomas J., Anderson, Mary Ann, Salem, Ahmed Hamed, Dunbar, Martin, Zhu, Ming, Peale, Franklin, Ross, Jeremy A., Gressick, Lori, Desai, Monali, Kim, Su Young, Verdugo, Maria, Humerickhouse, Rod A., Gordon, Gary B., Gerecitano, John F.
Materialtyp: Artigo
Språk:Inglês
Publicerad: American Society of Clinical Oncology 2017
Ämnen:
ORIGINAL REPORTS
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC5455685/
https://ncbi.nlm.nih.gov/pubmed/28095146
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2016.70.4320
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk